[ad_1]
(CNN) – Russia said Tuesday that its Sputnik V coronavirus vaccine is more than 91% effective, according to the latest data from its ongoing phase 3 trials.
Data obtained 28 days after the first dose and seven days after the second dose showed that the vaccine was 91.4% effective, according to a press release posted on the Sputnik-V Twitter account.
Preliminary data obtained 42 days after the first dose, 21 days after the second dose, indicate that the efficacy of the vaccine could be greater than 95%.
The Gamaleya National Research Center for Epidemiology and Microbiology hopes to publish data from the Phase 3 trials in an international medical journal after peer review, the statement continued.
Some experts have accused Russia of cutting corners with developing its vaccine, a claim Moscow has denied.
The calculations were based on analysis of data from 18,794 volunteers who received either the first and second doses of Sputnik V vaccine or placebo.
The latest interim analysis came after 39 confirmed cases of COVID-19 among phase 3 trial participants who received the vaccine or a placebo, according to the press release from Russia’s Direct Investment Fund and the Gamaleya Institute.
The statement added that there were no unexpected adverse events during the trials and monitoring of participants is ongoing.
Around 40,000 volunteers are participating in the phase 3 trials in Russia, of which more than 22,000 volunteers were vaccinated with the first dose and more than 19,000 with the first and second doses, according to the statement.
This story was first published on CNN.com, “Sputnik V Vaccine 91.4% Effective Based on Interim Data, Says Russia.”
[ad_2]
